Systems pharmacology reveals type I interferon and myeloid-like B cell reprogramming as candidate druggable axes in antiphospholipid syndrome

Bin Sun, Yiqiao Lu, Wei Liu, Chengze Wang · 2026

Read Systems pharmacology reveals type I interferon and myeloid-like B cell reprogramming as candidate druggable axes in antiphospholipid syndrome by Bin Sun, Yiqiao Lu, Wei Liu, Chengze Wang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0349155.txt.

Description

Bin Sun, Yiqiao Lu, Wei Liu, and Chengze Wang hunted for drug targets in antiphospholipid syndrome, an autoimmune clotting disorder with no targeted therapy, by layering several computational methods. Their 2026 systems pharmacology study combined gene network analysis of blood cells, single-cell sequencing of B cells, a drug signature database search, and molecular docking simulations.

Two gene programs stood out: one driven by type I interferon signaling, another by innate immune activation. Some B cells looked reprogrammed toward a myeloid-like state, an unexpected identity shift. Fourteen approved drugs touched the implicated genes, and a three-gene signature separated patients from controls decently. The authors offer the two programs as druggable axes awaiting laboratory and clinical testing, not as proven treatments.

Catalog record

CREATORBin Sun, Yiqiao Lu, Wei Liu, Chengze Wang
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE55837
LICENSECC_BY
RIGHTSCC BY
SOURCEPLOS

Source: https://doi.org/10.1371/journal.pone.0349155

Browse the full library · About the Tower of Babel